16 October 2013Americas

Enough is enough: sufficiency and technical contribution

The English High Court judgment in Lilly v Janssen, [2013] EWHC 1737(Pat) is a timely reminder of the difficulties of defending broad claims in the pharmaceutical and life science area.

Already registered?

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

Americas

Ligand buys biotech in $739m cash deal with litigation sweetener

28 April 2026 Pharma group strikes an all-cash transaction, combining a portfolio expansion with a contingent payment linked to a dispute over a $5 billion drug

Americas

CureVac targets Moderna with 10-patent suit over Spikevax

28 April 2026 BioNTech’s former rival—now part of its company—is seeking to assert its mRNA portfolio against Moderna in a new suit over modifications to the highly fought-over molecule.

Americas

Safeguarding critical IP in a high-risk era: WIPR Trade Secrets West 2026

28 April 2026 An event for IP, legal and compliance leaders to address the growing threat of trade secret misappropriation heads to San Jose.